Marta Vaz Batista, SABCS 2021: Preliminary Results From the DEBBRAH Phase II Study
Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021.
1. Could you tell us a little about trastuzumab deruxtecan and its potential advantages over other trastuzumab antibody-drug conjugates? 00:20-01:49
2. What are the objectives of the DEBBRAH Phase II study? 01:49-02:55
3. Could you tell us a little about the study cohorts and eligibility criteria of the study? 02:55-03:58
4. What have been the preliminary findings of the study? 03:58-06:33
5. Where do you expect trastuzumab deruxtecan to sit in the treatment paradigm for HER2+ or HER2-low-expressing advanced breast cancer? 06:33-08:40
Speaker Disclosure: Marta Vaz Batista discloses honoraria from Daiichi Sankyo.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!